Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Neuropsychopharmacol ; 16(1): 83-90, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22475622

RESUMEN

Major depressive disorder (MDD) is accompanied by both cognitive impairments and a hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system, resulting in an enhanced glucocorticoid secretion. Cortisol acts via mineralocorticoid and glucocorticoid receptors densely located in the hippocampus, a brain area that is important regarding cognitive functions and especially memory functions. Recently, a variant (rs1545843) affecting transcription of the human SLC6A15 gene has been associated with depression in a genome-wide association study. In an animal model, the neuronal amino acid transporter SLC6A15 was found to be decreased in stress-susceptible mice. Against the background of stress impacting on the activity of the HPA axis, we have investigated alterations of adrenocorticotropic hormone (ACTH) and cortisol secretion in the combined dexamethasone/corticotrophin-releasing hormone (Dex/CRH) test as well as memory and attention performance in a sample of 248 patients with unipolar depression and 172 healthy control subjects genotyped for rs1545843. MDD patients carrying the depression-associated AA genotype showed enhanced maximum and area under the curve ACTH and cortisol answers (p = 0.03) as well as an impaired memory and impaired sustained attention performance (p = 0.04) compared to carriers of at least one G allele. No effects of the SLC6A15 variant were found in the healthy control group. Our findings argue for a role of the SLC6A15 gene in ACTH and cortisol secretion during the Dex/CRH test and furthermore in the occurrence of cognitive impairments in unipolar depression.


Asunto(s)
Hormona Adrenocorticotrópica/sangre , Sistemas de Transporte de Aminoácidos Neutros/genética , Cognición/fisiología , Trastorno Depresivo/sangre , Trastorno Depresivo/genética , Hidrocortisona/sangre , Proteínas del Tejido Nervioso/genética , Adolescente , Hormona Adrenocorticotrópica/metabolismo , Adulto , Biomarcadores/sangre , Femenino , Variación Genética/genética , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple/genética , Adulto Joven
2.
Psychiatry Res ; 202(2): 96-103, 2012 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-22698761

RESUMEN

Major depressive disorder (MDD) is accompanied by morphological changes of brain structures which are of great importance in the neural circuitry mediating depression like the hippocampus and the amygdala. Hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system resulting in enhanced glucocorticoid secretion can often be observed during depression and has been thought to play an important role in inducing these morphological changes. We used magnetic resonance imaging to investigate alterations of amygdala and hippocampal volumes in 86 in-patients with unipolar depression and 87 healthy controls, and we then correlated amygdala and hippocampal volumes of 76 in-patients with the area under the curve of cortisol secretion in the dexamethasone/corticotropin releasing hormone (Dex/CRH) test at baseline and during short-term antidepressant therapy. In line with recently published studies both left and right amygdala volumes of patients in a first depressive episode were smaller than those of healthy controls. Patients with recurrent depressive episodes showed a reduction of hippocampal volumes, while amygdala volumes were normal. Larger left and right amygdala volumes correlated with a more pronounced reduction of HPA activity, measured by the cortisol secretion in the combined DEX/CRH test, during antidepressant therapy in patients with recurrent depressive episodes.


Asunto(s)
Amígdala del Cerebelo/patología , Trastorno Depresivo/metabolismo , Trastorno Depresivo/patología , Hidrocortisona/metabolismo , Adolescente , Hormona Adrenocorticotrópica , Adulto , Amígdala del Cerebelo/diagnóstico por imagen , Amígdala del Cerebelo/metabolismo , Análisis de Varianza , Área Bajo la Curva , Dexametasona , Femenino , Hipocampo/diagnóstico por imagen , Hipocampo/metabolismo , Hipocampo/patología , Humanos , Procesamiento de Imagen Asistido por Computador , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Cintigrafía , Adulto Joven
3.
Int J Neuropsychopharmacol ; 14(2): 237-45, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20701824

RESUMEN

Variant rs2522833 of the Piccolo-encoding gene PCLO has recently been found to be associated with major depressive disorder (MDD). PCLO encodes a presynaptic cytomatrix protein which influences monoamine neurotransmitter release. Piccolo could therefore play an important role in treatment response to antidepressant therapy and the improvement of alterations in HPA system reactivity. We investigated the influence of the coding variant rs2522833 in the PCLO gene on treatment response in 205 in-patients with unipolar depression. Treatment response was measured (1) at the level of psychopathology using the Hamilton Depression Rating Scale (HAMD) and (2) with the combined dexamethasone/corticotropin-releasing hormone (Dex/CRH) test, which is a refined tool for showing dysregulation of the hypothalamic-pituitary-adrenocortical (HPA) system, a neurobiological finding in depression. While we did not find an association between variation in PCLO and HAMD scores, HPA dysregulation was less pronounced in carriers of the AA genotype than in carriers of one or two C alleles. HPA activity of individuals with the AA genotype only marginally changed during 4-wk antidepressant treatment, whereas C allele carriers showed a higher hormonal secretion at admission than carriers of the AA genotype but lower responsivity to the Dex/CRH challenge after 4 wk. Our results point to a moderating role of PCLO SNP rs2522833 on HPA regulation during antidepressant treatment, which may represent a neurobiological feature of stability of clinical response.


Asunto(s)
Antidepresivos/uso terapéutico , Proteínas del Citoesqueleto/genética , Trastorno Depresivo Mayor/tratamiento farmacológico , Sistema Hipotálamo-Hipofisario/metabolismo , Neuropéptidos/genética , Sistema Hipófiso-Suprarrenal/metabolismo , Hormona Adrenocorticotrópica/sangre , Factores de Edad , Alelos , Área Bajo la Curva , Hormona Liberadora de Corticotropina , Proteínas del Citoesqueleto/metabolismo , Trastorno Depresivo Mayor/metabolismo , Dexametasona , Relación Dosis-Respuesta a Droga , Femenino , Genotipo , Humanos , Hidrocortisona/sangre , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Masculino , Neuropéptidos/metabolismo , Polimorfismo de Nucleótido Simple , Escalas de Valoración Psiquiátrica
4.
Int J Neuropsychopharmacol ; 13(5): 649-60, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20047716

RESUMEN

FKBP5 is a glucocorticoid receptor-regulating co-chaperone of hsp-90 and, therefore, is suggested to play a role in the regulation of the hypothalamic-pituitary-adrenocortical system and the pathophysiology of depression. Previously, three studies identified single nucleotide polymorphisms (SNPs) in the FKBP5 gene associated with response to antidepressants, and one study found an association with diagnosis of depression. We selected five markers from the region of interest. A case-control sample comprising 268 German in-patients with recurrent unipolar depression, and 284 German controls recruited from the general population were available. Association of the selected FKBP5 sequence variants with clinical depression were analysed. In addition, we explored association with treatment response by (a) the Hamilton Depression Rating Scale and (b) the dexamethasone/corticotrophin-releasing hormone (Dex/CRH) test, as well as association with hippocampal volumes in a subpopulation of 110 patients. For three of the five investigated SNPs we were able to show association with the diagnosis of depression. In the subpopulation of 110 patients, diagnosis-related alleles were also associated with the reduction of cortisol secretion in the Dex/CRH test during a 4-wk treatment period, while psychopathological changes were not associated. Furthermore, diagnosis-related alleles were associated with reduction of the hippocampal volume. This study extends the replicated association of a promoter SNP with antidepressant response on a biological level by demonstrating normalization of the cortisol response under Dex/CRH stimulation during treatment. Furthermore, several of the investigated SNPs were associated with the disease status and the intermediate phenotype of hippocampal volume.


Asunto(s)
Alelos , Secuencia de Bases/genética , Trastorno Depresivo/genética , Variación Genética/genética , Proteínas de Unión a Tacrolimus/genética , Adolescente , Adulto , Estudios de Casos y Controles , Citalopram/uso terapéutico , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/patología , Femenino , Ligamiento Genético/genética , Marcadores Genéticos/genética , Hipocampo/patología , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple/genética , Adulto Joven
5.
Schizophr Res ; 104(1-3): 71-8, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18656329

RESUMEN

BACKGROUND: Hippocampal volume reduction is a well replicated finding in schizophrenia. Evidence indicates a contribution of genetic and environmental factors, especially the influence of obstetric complications to this volume reduction. The aim of this study was to compare hippocampal volume of schizophrenic patients as well as and their relatives with control subjects and to quantify the additional contribution of obstetric complications. METHODS: T1 weighted MRI brain scans of 50 schizophrenic patients, 88 first-degree relatives and 53 healthy control subjects were used to perform volumetric measurements on the left and right hippocampus. A set of clinical measures including obstetric complications were recorded for all family members. RESULTS: Numerically our measurements revealed a hippocampal volume reduction in schizophrenic patients (left: -14%, right: -15%) and, although less pronounced, in their unaffected relatives (left: -6%, right: -10%). Noted differences in hippocampal volume between schizophrenic patients and controls were only significant for the left side. Hippocampal volumes of patients and their relatives with obstetric complications were reduced bilaterally. CONCLUSIONS: Hippocampal volume reduction is present in schizophrenic patients and their first-degree relatives, suggesting an influence of genetic factors. In addition, however, obstetric complications have also been shown to play a major role.


Asunto(s)
Hipocampo/anatomía & histología , Hipocampo/fisiopatología , Complicaciones del Trabajo de Parto/epidemiología , Esquizofrenia , Edad de Inicio , Estatura , Peso Corporal , Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/epidemiología , Femenino , Humanos , Inteligencia , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Variaciones Dependientes del Observador , Embarazo , Esquizofrenia/epidemiología , Esquizofrenia/genética , Esquizofrenia/fisiopatología
6.
Eur Arch Psychiatry Clin Neurosci ; 254(5): 303-11, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15365705

RESUMEN

Excess comorbidity between depression and epilepsy proposes common pathophysiological patterns in both disorders. Neuroendocrine abnormalities were often observed in depression as well as in epilepsy. Lack of inhibitory control of the hypothalamic pituitary adrenocortical (HPA) system is a core feature of depression; main relay stations of this system are located in the amygdala and hippocampus, which are key regions for both disorders. Therefore we explored the feedback mechanism of the HPA system in epilepsy. In order to control for the impact of depression we focused on epilepsies without depression. We compared patients with epilepsy (subdivided by medication with or without hepatic enzyme inducing antiepileptic medication) with 16 healthy controls and 16 patients with unipolar major depression but without epilepsy. We observed a lack of inhibitory control of the HPA system in patients with epilepsy, also in the absence of enzyme inducing medication. An impact of the temporal lobe location of the epileptic focus could not be observed. Thus, epilepsies share with depression the deficiencies in the feedback mechanism of the HPA system, proposing common pathophysiological features of up to now unknown nature.


Asunto(s)
Depresión/fisiopatología , Epilepsia/fisiopatología , Retroalimentación Fisiológica/fisiología , Sistema Hipotálamo-Hipofisario/fisiopatología , Sistema Hipófiso-Suprarrenal/fisiopatología , Hormona Adrenocorticotrópica/sangre , Adulto , Análisis de Varianza , Anticonvulsivantes/uso terapéutico , Área Bajo la Curva , Depresión/metabolismo , Dexametasona/administración & dosificación , Dexametasona/sangre , Epilepsia/sangre , Epilepsia/inducido químicamente , Epilepsia/tratamiento farmacológico , Retroalimentación Fisiológica/efectos de los fármacos , Femenino , Humanos , Hidrocortisona/sangre , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Masculino , Espectrometría de Masas/métodos , Persona de Mediana Edad , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Radioinmunoensayo , Estudios Retrospectivos , Factores de Tiempo
7.
J Psychiatr Res ; 38(4): 377-83, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15203289

RESUMEN

Previous research demonstrated that depression is associated with hyperactivity of the hypothalamus-pituitary-adrenocortical (HPA) system after stimulation. There is also strong evidence that the modulation of corticosteroids in the brain induces memory dysfunction which represents core features of depression. Antidepressant treatment with serotonin reuptake inhibitors (SSRIs) alleviates both dysfunctions. Thus, these previous observations propose a correlation between treatment induced changes of the endocrinological response of the HPA system to challenge with dexamethasone and CRH and changes of memory functions during antidepressant treatment. This study explores the relationship between depression, memory functions and the responsiveness of the HPA system as assessed by the combined DEX/CRH test during antidepressant treatment in n = 64 patients with major depression during a four weeks treatment with citalopram. We found that treatment induced changes of the cortisol response pattern in the DEX/CRH test were correlated with improvement of working memory but not so with episodic memory, sustained attention or global severity of depression. We suggest that improvement of working memory is more sensitive to the changes of hormones of the HPA system (e.g. cortisol) than other cognitive functions and the global severity of depression.


Asunto(s)
Antidepresivos de Segunda Generación/uso terapéutico , Citalopram/uso terapéutico , Cognición , Trastorno Depresivo/complicaciones , Trastorno Depresivo/tratamiento farmacológico , Sistema Hipotálamo-Hipofisario/fisiología , Memoria , Sistema Hipófiso-Suprarrenal/fisiología , Adulto , Anciano , Femenino , Humanos , Hidrocortisona/sangre , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Masculino , Persona de Mediana Edad , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Resultado del Tratamiento
8.
Psychiatry Res ; 132(3): 261-71, 2004 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-15664797

RESUMEN

There is some evidence for prefrontal (PF) lobe changes in schizophrenia while the parieto-occipital (PO) region seems to be unaffected. This magnetic resonance imaging (MRI) study was performed to examine shape differences as part of the spectrum of structural abnormalities in schizophrenia. The measurements were done on families affected with schizophrenia to identify the influence of genetic and environmental factors on these changes. The sample under study consisted of 164 subjects including 45 family members (FM) suffering from schizophrenia, 27 FM with other psychiatric disorders and 51 FM without psychiatric disorders based on ICD-10 criteria. In addition, 41 nonpsychiatric control subjects were included in the study. On defined planes at the corpus callosum boundary of the PF and the PO, brain width, height and length were measured on coronal slices. Ratios of these linear measurements were also calculated based on the idea that a plane can be approximated by a circle if the concerning ratio comes close to 1. It was hypothesized that these relative brain shape parameters, especially the PF ratio width/height, would show differences between schizophrenic patients and control subjects. For all members from families with schizophrenia compared with control subjects, there were significant differences in the PF, but not in the PO region. PF height was increased. PF ratios of width/height and height/(2 x length) were closer to 1 in affected families than in control subjects. The results can be interpreted as an indication for PF brain shape changes in subjects with a disposition for schizophrenia. On coronal and sagittal planes situated at the corpus callosum, their PF could be approximated by a circle better than in control subjects. As the frontal lobe takes shape late in brain development, underlying genetic mechanisms may be dysregulated in schizophrenic patients and subjects at risk to develop the disorder.


Asunto(s)
Imagenología Tridimensional , Imagen por Resonancia Magnética , Lóbulo Occipital/anatomía & histología , Lóbulo Parietal/anatomía & histología , Corteza Prefrontal/anatomía & histología , Esquizofrenia/diagnóstico , Adulto , Demografía , Femenino , Humanos , Clasificación Internacional de Enfermedades , Masculino
9.
Eur Arch Psychiatry Clin Neurosci ; 253(2): 92-9, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12799748

RESUMEN

Cerebrospinal fluid (CSF) space enlargement in schizophrenia is a prominent finding. This study was initiated to examine the influence of genetic loading, obstetric complications and premorbid adjustment on the extent of this enlargement. The sample of this MRI study consisted of 40 schizophrenic patients, 24 psychiatric and 40 healthy family members from 10 uniaffected and 19 multiple affected families with schizophrenia, such as 27 control subjects from non-affected families. The ventricle-to-brain-ratio (VBR), and the areas of the third ventricle, sylvian fissure, temporal horn and interhemispheric fissure at the slice where these structures reached their maximum were examined relatively to the corresponding total brain areas. The sum of CSF areas was calculated as a parameter for global atrophy. From MANCOVA adjusted for intervening variables the right VBR and the sum of CSF areas revealed significant differences between diagnostic groups. For these areas schizophrenic patients showed an increase compared to control subjects and family members with psychiatric disorder. Genetic loading influenced the interhemispheric fissure, enlarged in multiple affected compared to uniaffected families, and the temporal horn asymmetry, which was right sided (right > left) in control subjects and multiple affected families, but inverted in uniaffected families. Neonatal obstetric complications influenced only the size of the VBR, while premorbid adjustment predicted various CSF areas. In conclusion, schizophrenic subjects from multiple and uniaffected families showed a global atrophy, which was most pronounced in the VBR. Genetic loading seems to have an impact on frontal regions as the interhemispheric fissure and on the temporal horn.


Asunto(s)
Encéfalo/patología , Complicaciones del Trabajo de Parto , Esquizofrenia/etiología , Esquizofrenia/patología , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Ventrículos Cerebrales/patología , Femenino , Predisposición Genética a la Enfermedad , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Embarazo , Esquizofrenia/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...